Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Safety of FB-401 in Atopic Dermatitis
NCT04936113Phase 2Terminated
- Sponsor
- Forte Biosciences, Inc.
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of FB-401 in atopic dermatitis (AD), sponsored by Forte Biosciences, Inc.. Started Jun 2021; status: terminated.
02
Drugs
FB-401
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04936113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936113.